Use of mesenchymal stem cells or autologous conditioned serum to modulate the inflammatory response to spermatozoa in mares

Theriogenology

Volumn 82, Issue 1, 2014, Pages 36-42

  Ferris, Ryan A ^a   Frisbie, David D ^a   McCue, Patrick M ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Autologous conditioned serum; Endometritis; Mare; Mesenchymal stem cell; Therapy

Indexed keywords

DEXAMETHASONE;

ANIMAL; BREEDING; ENDOMETRITIS; EVALUATION STUDY; FEMALE; HORSE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; PHYSIOLOGY; PROCEDURES; SPERMATOZOON;

ANIMALS; BREEDING; DEXAMETHASONE; ENDOMETRITIS; FEMALE; HORSES; IMMUNOSUPPRESSION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; SPERMATOZOA;

EID: 84901452089     PISSN: 0093691X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.theriogenology.2014.02.015     Document Type: Article

References (35)

1. Traub-Dargatz J.L., Salman M.D., Voss J.L. Medical problems of adult horses, as ranked by equine practitioners. J Am Vet Med Assoc 1991, 198:1745-1747.
2. Troedsson M.H., Loset K., Alghamdi A.M., Dahms B., Crabo B.G. Interaction between equine semen and the endometrium: the inflammatory response to semen. Anim Reprod Sci 2001, 68:273-278.
3. Zent W., Troedsson M., Xue J.-L. Postbreeding uterine fluid accumulation in a normal population of thoroughbred mares: a field study. Proc Am Assoc Equine Pract 1998, 64-65.
4. Neely D.P., Kindahl H., Stabenfeldt G.H., Edqvist L.E., Hughes J.P. Prostaglandin release patterns in the mare: physiological, pathophysiological, and therapeutic responses. J Reprod Fertil Suppl 1979, 27:181-189.
5. Betteridge K.J., Eaglesome M.D., Mitchell D., Flood P.F., Beriault R. Development of horse embryos up to twenty two days afterovulation: observations on fresh specimens. J Anat 1982, 135:191-209.
6. Parham P. The immune system 2009, Garland Science, New York. Third edition.
7. Fumuso E., Giguere S., Wade J., Rogan D., Videla-Dorna I., Bowden R.A. Endometrial IL-1β, IL-6 and TNF-α, mRNA expression in mares resistant or susceptible to post-breeding endometritis. Vet Immunol Immunopathol 2003, 96:31-41.
8. Fumuso E., Aguilar J., Giguere S., David O., Wade J., Rogan D. Interleukin-8 (IL-8) and 10 (IL-10) mRNA transcriptions in the equine endometrium of normal mares and mares susceptible to persistent post-breeding endometritis. Anim Reprod Sci 2006, 94:282-285.
9. Woodward E.M., Christoffersen M., Campos J., Betancourt A., Horohov D., Scoggin K.E., et al. Endometrial inflammatory markers of the early immune response in mares susceptible or resistant to persistent breeding-induced endometritis. Reproduction 2013, 145:289-296.
10. Rasch K., Schoon H.A., Sieme H., Klug E. Histomorphological endometrial status and influence of oxytocin on the uterine drainage and pregnancy rate in mares. Equine Vet J 1996, 28:455-460.
11. Leblanc M., Neuwirth L., Mauragis D., Klapstein E., Tran T. Oxytocin enhances clearance of radiocolloid from the uterine lumen of reproductively normal mares and mares susceptible to endometritis. Equine Vet J 1994, 26:279-282.
12. Pycock J.F., Newcombe J.R. Assessment of the effect of three treatments to remove intrauterine fluid on pregnancy rate in the mare. Vet Rec 1996, 138:320-323.
13. Troedsson M., Scott M., Liu I. Comparative treatment of mares susceptible to chronic uterine infection. Am J Vet Res 1995, 56:468-472.
14. Nie G. Effect of administering oxytocin or cloprostenol in the periovulatory period on pregnancy outcome and luteal function in mares. Theriogenology 2003, 60:1111-1118.
15. Bucca S., Carli A., Buckley T., Dolci G., Fogarty U. The use of dexamethasone administered to mares at breeding time in the modulation of persistent mating induced endometritis. Theriogenology 2008, 70:1093-1100.
16. Iyer S.S., Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther 2008, 8:569-581.
17. Le Blanc K., Rasmusson I., Sundberg B., Götherström C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
18. da Silva Meirelles L., Caplan A.I., Nardi N.B. In search of the invivo identity of mesenchymal stem cells. Stem Cells 2008, 26:2287-2299.
19. da Silva Meirelles L., Fontes A.M., Covas D.T., Caplan A.I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009, 20:419-427.
20. Ortiz L.A., DuTreil M., Fattman C.A., Pandey C., Torres G., Go K., et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci 2007, 104:11002-11007.
21. Singer N.G., Caplan A.I. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011, 6:457-478.
22. Frisbie D.D., Smith R. Clinical update on the use of mesenchymal stem cells in equine orthopaedics. Equine Vet J 2012, 42:86-89.
23. Wright-Carpenter T., Opolon P., Appell H.J., Meijer H., Wehling P., Mir L.M. Treatment of muscle injuries by local administration of autologous conditioned serum: animal experiments using a muscle contusion model. Int J Sports Med 2004, 25:582-587.
24. Hraha T.H., Doremus K.M., McIlwraith C.W., Frisbie D.D. Autologous conditioned serum: the comparative cytokine profiles of two commercial methods (IRAP and IRAP II) using equine blood. Equine Vet J 2011, 43:516-521.
25. Goldring M.B., Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators. Clin Orthop Relat Res 2004, 427:37-46.
26. Frisbie D.D., Ghivizzani S.C., Robbins P.D., Evans C.H., McIlwraith C.W. Treatment of experimental equine osteoarthritis by invivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002, 9:12-20.
27. Baltzer A., Moser C., Jansen S. Autologous conditioned serum (orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009, 17:152-160.
28. Yang K.G.A., Raijmakers N.J.H., van Arkel E.R.A., Caron J.J., Rijk P.C., Willems W.J., et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008, 16:498-505.
29. Wehling P., Moser C., Frisbie D., McIlwraith C.W., Kawcak C.E., Krauspe R., et al. Autologous conditioned serum in the treatment of orthopedic diseases - the orthokine therapy. Biodrugs 2007, 21:323-332.
30. Fioratti E.G., Villaverde A.I.S.B., Melo C.M., Tsunemi M.H., Papa F.O., Alvarenga M.A. Influence of steroidal anti-inflammatory drugs on viability and fertility of equine semen. J Equine Vet Sci 2012, 32:771-775.
31. Frisbie D.D., Kisiday J.D., Kawcak C.E. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. J Orthop Res 2009, 27:1675-1680.
32. Ferris R.A., McCue P.M. The effects of dexamethasone and prednisolone on pituitary and ovarian function in the mare. Equine Vet J 2010, 42:438-443.
33. Kotilainen T., Huhtinen M., Katila T. Sperm-induced leukocytosis in the equine uterus. Theriogenology 1994, 41:629-636.
34. Iyer S.S., Rojas M. Anti-inflammatory effects of mesenchymal stem cells: a review. Expert Opin Biol Ther 2011, 21:1-14.
35. Rojas M. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005, 33:145-152.